研究目的
Determination of HER2-ECD and cancer cells in biological samples is critical for an efficient diagnosis and follow-up of (eventually) HER2-positive breast cancer.
研究成果
The immunomagnetic assay proved to be a fast, reliable and specific analytical tool for measuring tumour markers in cancer patients' serum.
研究不足
One of the limitations of the assay is the use of a heavy metal for detection purposes. The generated waste can selectively be collected and sent to a certified entity operating in accordance with European standards regarding waste management.
1：Experimental Design and Method Selection
An electrochemical magnetic immunosensing strategy was developed using carboxylic acid-functionalized magnetic beads (MBs) and a screen-printed carbon electrode (SPCE) as transducer surface. The affinity process was detected using core/shell streptavidin-modified CdSe@ZnS Quantum Dots (QDs) as electroactive labels.
2：Sample Selection and Data Sources
Human serum samples were used to test the sensor's applicability. Breast cancer cell lines SK-BR-3, MDA-MB-231, and MCF-7 were tested for the analysis of live breast cancer cells.
3：List of Experimental Equipment and Materials
Screen-printed carbon electrodes (SPCE, DRP-110), potentiostat/galvanostat (Autolab PGSTAT204), DynaMag?-2 magnet, FEI Quanta 400FEG ESEM/EDAX Genesis X4 M equipment, Nikon TMS microscope, automated cell counter (Countess?, ThermoFisher Scientific - Invitrogen), Millipore water purification system (Simplicity 185).
4：Experimental Procedures and Operational Workflow
The assay involved biomodification of MBs, magnetic immunoassay steps including incubation with analyte and detection antibody, and electrochemical analysis using DPASV.
5：Data Analysis Methods
Differential pulse anodic stripping voltammetry (DPASV) was used for the determination of Cd2+ ions released from the QDs.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
